Starling Oncology Institute, Inc. Common Stock
STLN
50 hedge funds and large institutions have $261M invested in Starling Oncology Institute, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 13 increasing their positions, 17 reducing their positions, and 8 closing their positions.
31.21% more ownership
Funds ownership: 82.55% → 113.76% (+31%)
27% more capital invested
Capital invested by funds: $205M → $261M (+$55.6M)
13% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 8
2% more funds holding
Funds holding: 49 → 50 (+1)
24% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$53.3M |
| 2 |
DKCM
Davidson Kempner Capital Management
New York
|
+$11.1M |
| 3 |
PWAM
Park West Asset Management
San Francisco,
California
|
+$7.98M |
| 4 |
TAL
TIG Advisors LLC
New York
|
+$6.26M |
| 5 |
KLC
Kent Lake Capital
Reno,
Nevada
|
+$5.79M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SRCM
Sage Rock Capital Management
New York
|
-$4.77M |
| 2 |
ECM
Element Capital Management
New York
|
-$2.67M |
| 3 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$2.62M |
| 4 |
PMAM
Picton Mahoney Asset Management
Toronto,
Ontario, Canada
|
-$2.16M |
| 5 |
KC
Kepos Capital
New York
|
-$1.29M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PMAM
51
Picton Mahoney Asset Management
Toronto,
Ontario, Canada
| – | -$2.16M | -200,000 | Closed |
|
52
Goldman Sachs
New York
| – | -$810K | -75,000 | Closed |
|
|
JG
53
Jefferies Group
New York
| – | -$432K | -40,000 | Closed |
|
|
MSU
54
Mizuho Securities USA
New York
| – | -$262K | -25,000 | Closed |
|
|
SCM
55
Saba Capital Management
New York
| – | -$187K | -17,318 | Closed |
|
56
Geode Capital Management
Boston,
Massachusetts
| – | -$113K | -10,327 | Closed |
|
57
UBS Group
Zurich,
Switzerland
| – | -$5K | -502 | Closed |
|
|
TRCT
58
Tower Research Capital (TRC)
New York
| – | +$511 | +48 | +4,800% |
|
STLN Hedge Fund Activity: Q1 2021 in Review
50 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Starling Oncology Institute, Inc. Common Stock (STLN) for Q1 2021, worth a combined $261M — up 27% from $205M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new STLN positions and 8 closed out — a net gain of 1 holder — while 13 added to existing stakes and 17 trimmed.
The largest buyer was Deerfield Management, adding an estimated $53.3M. The largest seller was Sage Rock Capital Management, cutting an estimated $4.77M.
- 50 institutional investors held Starling Oncology Institute, Inc. Common Stock (STLN) as of Q1 2021, up from 49 in Q4 2020.
- Funds reported $261M of Starling Oncology Institute, Inc. Common Stock stock for Q1 2021, up 27% quarter-over-quarter.
- 9 funds opened new Starling Oncology Institute, Inc. Common Stock positions in Q1 2021 and 8 closed out, a net change of +1 holder.
- The largest Starling Oncology Institute, Inc. Common Stock buyer in Q1 2021 was Deerfield Management, an estimated $53.3M added.
- The largest Starling Oncology Institute, Inc. Common Stock seller in Q1 2021 was Sage Rock Capital Management, an estimated $4.77M sold.
Based on aggregated 13F filings for Q1 2021.